Andrea Ahnmark
Overview
Explore the profile of Andrea Ahnmark including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
434
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Palmgren H, Petkevicius K, Bartesaghi S, Ahnmark A, Ruiz M, Nilsson R, et al.
Diabetes
. 2022 Dec;
72(10):1350-1363.
PMID: 36580483
Increased saturated fatty acid (SFA) levels in membrane phospholipids have been implicated in the development of metabolic disease. Here, we tested the hypothesis that increased SFA content in cell membranes...
2.
Nag A, Dhindsa R, Mitchell J, Vasavda C, Harper A, Vitsios D, et al.
Sci Adv
. 2022 Nov;
8(46):eadd5430.
PMID: 36383675
We performed collapsing analyses on 454,796 UK Biobank (UKB) exomes to detect gene-level associations with diabetes. Recessive carriers of nonsynonymous variants in were 30% less likely to develop diabetes (...
3.
Petkevicius K, Palmgren H, Glover M, Ahnmark A, Andreasson A, Madeyski-Bengtson K, et al.
Nat Commun
. 2022 Oct;
13(1):6020.
PMID: 36241646
The fatty acid composition of phosphatidylethanolamine (PE) determines cellular metabolism, oxidative stress, and inflammation. However, our understanding of how cells regulate PE composition is limited. Here, we identify a genetic...
4.
Karlsson D, Ahnmark A, Sabirsh A, Andreasson A, Gennemark P, Sandinge A, et al.
Biomedicines
. 2022 Feb;
10(2).
PMID: 35203411
Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used for the treatment of diabetes. This study examines the effects of dapagliflozin on human islets, focusing on alpha and beta cell...
5.
Kroon T, Harms M, Maurer S, Bonnet L, Alexandersson I, Lindblom A, et al.
Mol Metab
. 2020 Apr;
36:100964.
PMID: 32248079
Objective: Peroxisome proliferator-activated receptors (PPARs) are key transcription factors that regulate adipose development and function, and the conversion of white into brown-like adipocytes. Here we investigated whether PPARα and PPARγ...
6.
Lee S, Priest C, Bjursell M, Gao J, Arneson D, Ahn I, et al.
Nat Metab
. 2020 Feb;
1(11):1089-1100.
PMID: 32072135
Liver X receptors limit cellular lipid uptake by stimulating the transcription of Inducible Degrader of the LDL Receptor (IDOL), an E3 ubiquitin ligase that targets lipoprotein receptors for degradation. The...
7.
Linden D, Ahnmark A, Pingitore P, Ciociola E, Ahlstedt I, Andreasson A, et al.
Mol Metab
. 2019 Feb;
22:49-61.
PMID: 30772256
Objective: Nonalcoholic fatty liver disease (NAFLD) is becoming a leading cause of advanced chronic liver disease. The progression of NAFLD, including nonalcoholic steatohepatitis (NASH), has a strong genetic component, and...
8.
Buss N, Lapointe J, de Haan L, Price S, Ahnmark A, Irving L, et al.
Toxicol Appl Pharmacol
. 2018 Jul;
355:147-155.
PMID: 30008375
Fibroblast Growth Factors (FGFs) and their receptors (FGFRs) have been proposed as potential drug targets for the treatment of obesity. The aim of this study was to assess the potential...
9.
Hansson S, Zhou A, Vachet P, Eriksson J, Pereira M, Skrtic S, et al.
PLoS One
. 2018 Apr;
13(4):e0196601.
PMID: 29702679
Beta cell dysfunction accompanies and drives the progression of type 2 diabetes mellitus (T2D), but there are few clinical biomarkers available to assess islet cell stress in humans. Secretagogin, a...
10.
Sundstrom L, Myhre S, Sundqvist M, Ahnmark A, McCoull W, Raubo P, et al.
PLoS One
. 2017 Dec;
12(12):e0189060.
PMID: 29206860
The mechanism behind the glucose lowering effect occurring after specific activation of GPR120 is not completely understood. In this study, a potent and selective GPR120 agonist was developed and its...